Key Takeaways The S&P 500 added 1.1% on Wednesday, March 19, 2025, as the Fed held interest rates steady, reaffirming plans ...

Shares of Gilead Sciences (GILD) fell 2% on Wednesday following a Wall Street Journal report that the Trump administration is ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

The Department of Health and Human Services is reportedly poised to slash funding for domestic HIV prevention at the Centers for Disease Control and Prevention, the Wall Street Journal fi | Top ...

Gilead Sci­ences’ stock $GILD dropped by more than 3% on Wednes­day af­ter­noon amid re­ports that the US will slash ...

Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal funding for domestic HIV ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is ...

The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the ...

The Health and Human Services Department is weighing plans to drastically cut funding for domestic HIV prevention, The Wall Street Journal reported. + The cuts could af ...